Dusseldorf - Delayed Quote EUR
Abivax SA (2X10.DU)
5.80
0.00
(0.00%)
As of April 24 at 8:12:42 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
--
--
--
50,764
45,517
Gross Profit
--
--
--
-50,764
-45,517
Operating Expense
172,984
172,984
127,377
51,205
41,398
Operating Income
-172,984
-172,984
-127,377
-51,205
-41,398
Net Non Operating Interest Income Expense
-4,564
-4,564
-12,708
-6,717
-3,476
Other Income Expense
1,307
1,307
-7,654
-2,820
2,425
Pretax Income
-176,242
-176,242
-147,740
-60,740
-42,452
Net Income Common Stockholders
-176,242
-176,242
-147,740
-60,740
-42,452
Diluted NI Available to Com Stockholders
-176,242
-176,242
-147,740
-60,740
-42,452
Basic EPS
-3.43
-2.80
-3.43
-3.18
-2.75
Diluted EPS
-3.43
-2.80
-3.43
-3.18
-2.75
Basic Average Shares
43,066.01
63,046.35
43,066.01
19,092.44
15,455.99
Diluted Average Shares
43,066.01
63,046.35
43,066.01
19,092.44
15,455.99
Total Operating Income as Reported
-172,984
-172,984
-127,376
-64,836
-41,400
Rent Expense Supplemental
482
--
--
1,048
548
Total Expenses
172,984
172,984
127,377
51,205
41,398
Net Income from Continuing & Discontinued Operation
-176,242
-176,242
-147,740
-60,740
-42,452
Normalized Income
-177,549
-177,549
-140,086
-57,920
-44,877
Interest Income
8,956
8,956
2,773
--
--
Interest Expense
12,431
12,431
13,826
6,940
3,558
Net Interest Income
-4,564
-4,564
-12,708
-6,717
-3,476
EBIT
-163,811
-163,811
-133,914
-53,800
-38,894
EBITDA
-162,711
-162,711
-133,207
-53,315
-38,592
Reconciled Cost of Revenue
--
--
--
50,526
45,517
Reconciled Depreciation
1,100
1,100
707
485
302
Net Income from Continuing Operation Net Minority Interest
-176,242
-176,242
-147,740
-60,740
-42,452
Total Unusual Items Excluding Goodwill
1,307
1,307
-7,654
-2,820
2,425
Total Unusual Items
1,307
1,307
-7,654
-2,820
2,425
Normalized EBITDA
-164,018
-164,018
-125,553
-50,495
-41,017
12/31/2021 - 3/6/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BTTAY Biotest Aktiengesellschaft
24.23
+6.27%
3EE0.F Kancera AB (publ)
0.0980
0.00%
2DE0.F Genprex, Inc.
0.0000
-100.00%
5IU.F Isofol Medical AB (publ)
0.1578
0.00%
0RU9.IL 0RU9.IL,0P0000KJ6A,0
1,147,190.00
0.00%
2KZ0.F Kezar Life Sciences, Inc.
3.9000
0.00%
0T20.F Traws Pharma, Inc.
0.0000
-100.00%
2I9.F Karolinska Development AB (publ)
0.0671
0.00%
1HB0.F Scorpius Holdings, Inc.
0.0000
-100.00%
B1Q.F NRX Pharmaceuticals Inc. R
1.5900
0.00%